Posted by Michael Wonder on 19 Sep 2023
Cellectar Biosciences receives European Medicines Agency Priority Medicines (PRIME) designation for iopofosine for Waldenstrom’s macroglobulinaemia
18 September 2023 - The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options.
Cellectar Biosciences today announced that the EMA has granted priority medicines (PRIME) designation to iopofosine I 131, the company’s lead small-molecule drug candidate, for Waldenstrom’s macroglobulinaemia in patients who have received two or more prior treatment regimens.
